Clinical Features and Prognosis of Invasive Pulmonary Aspergillosis in Korean Children with Hematologic/Oncologic Diseases

Seung Beom Han,1,2 Seong koo Kim,1,3 E Young Bae,1,2 Jae Wook Lee,1,3 Jong-Soe Yoon,1,2 Nack-Gyun Chung,1,3 Bin Cho,1,3 Dae Chul Jeong,1 Jin Han Kang,1,3 Hack-Ki Kim,1,3 Dong-Gun Lee,1,3,4 Hyun Sil Lee,5 and Soo Ah Im1

1Department of Pediatrics, 2Vaccine Bio Research Institute, 3Catholic Blood and Marrow Transplantation Center, Division of Infectious Diseases, Department of Internal Medicine, and 4Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul, Korea

Received: 24 December 2014
Accepted: 27 April 2015

Address for Correspondence:
Jong-Soe Yoon, MD
Department of Pediatrics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea
Tel: +82-2-2258-6190, Fax: +82-2-537-4544
E-mail: pedjsyoon@catholic.ac.kr

INTRODUCTION

Aspergillus spp. became the most common pathogen causing invasive fungal disease (IFD) in immunocompromised patients after the introduction of fluconazole prophylaxis; therefore, invasive aspergillosis (IA) is the most common type of IFD in these patients (1-3). Immunocompromised patients with IA have a high mortality of 40%-50% (4-6), and mortality up to 70% has been reported in pediatric cancer patients with IA (7). In spite of the introduction of newer antifungal agents, such as voriconazole and echinocandins, which have an improved effect on IA, the mortality of IA was recently reported as 25%-35% (8-11). A relatively higher mortality of 40%-50% due to IA is still cited in situations where amphotericin B deoxycholate was administered as the first line antifungal agent, as in Korea where availability of first line antifungal agents was limited to amphotericin B deoxycholate or itraconazole under government regulations of the national health insurance system (12-14).

Invasive pulmonary aspergillosis (IPA) is the most frequent form of invasive fungal diseases in immunocompromised patients. However, there are only a few studies on IPA in immunocompromised children in Korea. This study was designed to characterize IPA in Korean children with hematologic/oncologic diseases. Medical records of children with hematologic/oncologic diseases receiving antifungal therapy were reviewed. The enrolled children were divided into the IPA group (proven and probable IPA) and non-IPA group, and the clinical characteristics and prognosis were compared between the two groups. During the study period, 265 courses of antifungal therapy were administered to 166 children. Among them, two (0.8%) episodes of proven IPA, 35 (13.2%) of probable IPA, and 52 (19.6%) of possible IPA were diagnosed. More children in the IPA group suffered from neutropenia lasting for more than two weeks (51.4% vs. 21.9%, P < 0.001) and showed halo signs on the chest computed tomography (78.4% vs. 40.7%, P < 0.001) than in the non-IPA group. No other clinical factors showed significant differences between the two groups. Amphotericin B deoxycholate was administered as a first line antifungal agent in 33 (89.2%) IPA group episodes, and eventually voriconazole was administered in 27 (73.0%) episodes. Ten (27.0%) children in the IPA group died within 12 weeks of antifungal therapy. In conclusion, early use of chest computed tomography to identify halo signs in immunocompromised children who are expected to have prolonged neutropenia can be helpful for early diagnosis of IPA and improving prognosis of children with IPA.

Keywords: Invasive Pulmonary Aspergillosis; Immunocompromised Host; Child

Given the high mortality of IA and improved prognosis with an early diagnosis and antifungal treatment (15, 16), empirical or pre-emptive antifungal therapy with antifungal agents having an anti-mold effect has been recommended in immunocompromised patients with risk factors for IA (17, 18). On the other hand, universal empirical therapy in patients at risk for IA may expose those patients without a true fungal infection to unnecessary antifungal agents, and this may result in unwanted adverse effects and increased medical costs. Actually, only 8%-20% of patients with hematologic/oncologic diseases who received empirical antifungal therapy were reported to have true IFD (19-21).

In Korea where empirical antifungal therapy has been standard practice for children with hematologic/oncologic diseases, epidemiological data on IFD or IA in those children is scarce (12). The aim of this retrospective study was to investigate the clinical features and prognosis of invasive pulmonary aspergillosis (IPA) in Korean children with hematologic/oncologic dis-
eases. This study was conducted with consideration of the fact that IA is the most frequent of IFD in immunocompromised patients and most cases of IA are IPA (3, 11, 12, 15, 22, 23).

MATERIALS AND METHODS

Subjects and study design
Medical records of children (<20 yr of age) with hematologic/oncologic diseases, who were admitted to Seoul St. Mary’s Hospital, Seoul, Korea between April 2009 and March 2013 were retrospectively reviewed. Among them, children who received antifungal therapy with agents having an anti-mold effect for more than 48 hr were enrolled. The enrolled children were diagnosed with possible, probable, or proven IPA based on the revised definition of IFD in immunocompromised patients recommended by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC-MSG) Consensus Group in 2008 (24). Children with IA not involving the lung were excluded. Children diagnosed with proven and possible IPA were included in the IPA group, whereas children diagnosed with possible IPA and those who did not fulfill the diagnostic criteria for three categories of IPA were included in the non-IPA group. In the event that one child experienced several episodes of IPA, IPA diagnosed after the cessation of antifungal therapy for a previous episode of IPA was considered a separate episode of IPA and included in the present study. Clinical features of the IPA group were investigated, and clinical factors related to the development of IPA were evaluated by comparing clinical features of the IPA and non-IPA groups. The evaluated clinical features included sex, age, the type of underlying hematologic/oncologic disease and its remission status, the type of therapy administered prior to antifungal therapy, the duration of fever and neutropenia, previous histories of IPA and hematopoietic cell transplantation (HCT), and the presence of concurrent infections. In addition, mortality at 6 and 12 weeks after antifungal therapy was compared between the IPA and non-IPA groups.

Institutional strategies for antifungal therapy
In our hospital, antifungal prophylaxis and empirical antifungal therapy have been given based on the recommendations of the committee for “Guidelines for the Empirical Therapy of Neutropenic Fever Patients based on Literature in Korea” (25). Antifungal prophylaxis with oral fluconazole (3 to 5 mg/kg/day) was given from the initiation of anti-cancer chemotherapy until recovery from neutropenia. In children who received HCT, intravenous micafungin (1 mg/kg/day) prophylaxis was given from the start of pre-HCT conditioning therapy to engraftment, and then oral fluconazole was given until the discontinuation of immune suppressants. Empirical antifungal therapy was administered when fever lasted for 3 to 5 days in children who were expected to have neutropenia for longer than seven days or who received immune suppressants after allogeneic HCT. If chest computed tomography (CT) findings consistent with fungal pneumonia or positive serum galactomannan index (GMI) were observed, pre-emptive antifungal therapy was given regardless of the duration of fever. Serum GMI was tested once or twice a week during neutropenia in children receiving anti-cancer chemotherapy and from pre-HCT conditioning therapy until discharge from hospital in children receiving HCT. Chest CT was performed in children with abnormal findings on chest x-ray or positive serum GMI.

Definition
The diagnosis of IPA was based on the definition of IFD recommended by the EORTC-MSG Consensus Group, which was applicable to patients with host factors of compromised immunity (24). Proven IPA was defined as when Aspergillus spp. were observed with accompanying tissue damage or Aspergillus spp. were identified in culture on sterile materials (24). Probable IPA was defined as when clinical features and mycological evidence for IPA were observed in patients with host factors, and possible IPA was defined as the presence of clinical features of IPA without mycological evidence (24). One of the chest CT findings among well-circumscribed lesions with or without halo sign (consolidation and surrounding ground glass opacity), air-crescent sign and cavity fulfills clinical criteria for IPA, and mycological criteria consisted of the presence of mold or identification of Aspergillus spp. from culture of sputum, bronchoalveolar lavage (BAL) fluid or bronchial brush and positive GMI from serum, plasma or BAL fluid (24). Neutropenia was defined as a neutrophil count < 500/μL (24), and chest CT was reviewed by two independent radiologists (HYL and SAI). The GMI was measured using the PLATELIA™ ASPERGILLUS EIA kit (Bio-Rad, Marnes-la-Coquette, France) in accordance with the manufacturer’s recommendations. Serum GMI > 0.5 and BAL fluid GMI > 1.0 were defined as positive based on the 4th European Conference on Infections in Leukemia (ECIL-4) guidelines (17). Positive GMI results were confirmed by a repeat measurement of GMI in the same sample. Because it was difficult to clearly define whether immunocompromised patients with IPA died of IPA or other complicated causes (26), overall mortality at 6 and 12 weeks after antifungal therapy were evaluated.

Statistical analysis
Categorical variables were compared using the chi-square test and continuous variables were compared using student’s t-test or the Mann-Whitney test based on the distribution of the data. Fischer’s exact test was used to compare the incidence of IPA during the study period. Mortality at 12 weeks after antifungal therapy was compared between the IPA and non-IPA groups.
using a log-rank test. Statistical analysis was performed using
SPSS Statistics 17.0 (SPSS Inc., Chicago, IL, USA), and statistical
significance was defined as a two-tailed P value < 0.05.

Ethics statement
This study was approved by the institutional review board of the
Seoul St. Mary’s Hospital with an exemption of acquiring inform-
ed consent (Approval No.: KC14RISI0791).

RESULTS
A total of 268 courses of antifungal therapy with anti-mold agents
were administered to 168 children. Among them, one episode
of probable cerebral IA and two cases of possible fungal sinus-
itis without involvement of the lung were excluded. Among the
remaining 265 courses of antifungal therapy, 52 (19.6%) episodes
of possible IPA, 35 (13.2%) episodes of probable IPA, and two
(0.8%) episodes of proven IPA were diagnosed. Accordingly, 37
(14.0%) and 228 (86.0%) episodes were included in the IPA and
non-IPA groups, respectively. Candidemia was diagnosed in
eight (3.1%) episodes of the non-IPA group, and IFD caused by
other fungi was not reported. The yearly distribution of IPA was
not significantly different during the study period (Fig. 1, P =
0.603).

Characteristics of children with invasive pulmonary
aspergillosis
The mean age of children in the IPA group was 11.4 ± 5.3 yr, and
23 (62.2%) episodes of IPA were diagnosed in boys (Table 1).
Acute myeloid leukemia (AML) and acute lymphoblastic leu-
kemia (ALL) were the most common underlying diseases, and
23 (74.2%) episodes were diagnosed in non-complete remis-
sion (CR) of the underlying hematologic malignancies. In accordance
with these results, re-induction or salvage chemotherapy was
the most common therapy preceding antifungal therapy (35.1%),
and allogeneic HCT was the next most common (16.2%).

Prolonged neutropenia lasting for longer than 10 days was
most frequent among the host factors for defining IFD recom-
manded by the EORTC-MSG Consensus Group (Table 2). A halo
sign was the most common finding on chest CT, and serum GMI
was positive in 30 (81.1%) episodes. BAL fluid analyses were per-
formed in 11 episodes, and BAL fluid GMI was positive in six
(54.5%) episodes. Both serum and BAL fluid GMIs were posi-
tive in one (2.7%) episode. In the five episodes of BAL cases, BAL
fluid GMI were negative, despite of positive serum GMIs. Accord-
ing to GMI results by specimen, BAL fluid(+)/serum(-) group
and BAL fluid(-)/serum(+) group showed no significant differ-
ences in host factors or in clinical presentation. Bronchoscopy
was performed earlier after starting antifungal therapy in the
BAL fluid(+)/serum(-) group than in the BAL fluid(-)/serum(+) group,
although statistically insignificant (median 3 days, inter-
quartile range [IQR]: 1-12 vs. median 6 days, IQR: 1-11 days,
P = 0.173). Aspergillus spp. were identified in BAL fluid cultures in
two episodes. Two children diagnosed with proven IPA under-
went a pulmonary lobectomy, and the Aspergillus spp. were iden-
tified in their excised lung tissue.

Antifungal prophylaxis was performed in 26 (70.3%) episodes,
and fluconazole (5 to 10 mg/kg/day) was administered most
frequently (Table 3). Amphotericin B deoxycholate was admin-
istered as the first line antifungal agent, amphotericin B
deoxycholate was changed to a second line antifungal agent in
35 (94.6%) of 37 episodes a median of 4 days (IQR: 2-7) later.
Among 33 episodes in which amphotericin B deoxycholate was
administered as the first line antifungal agent, amphotericin B
deoxycholate was changed to a second line antifungal agent in
32 (97.0%) episodes. Oral voriconazole was given as a second
line agent on discharge from the hospital in three (9.4%) episo-
des, and intravenous voriconazole was given with a diagnosis
of probable IPA in four (12.5%) episodes. Oral voriconazole was given as a second
line agent on discharge from the hospital in three (9.4%) episo-
des, and intravenous voriconazole was given with a diagnosis
of probable IPA in four (12.5%) episodes. In six (18.8%) episodes,
second line agents were administered due to sustained fever
lasting for more than five days in spite of first line antifungal ther-
apy. In the remaining 22 (68.8%) episodes, second line antifun-
gal agents were given due to adverse effects of first line agents.

Infusion-related adverse effects of amphotericin B deox-
chyolate were reported in 18 (56.3%) episodes, including 14 cases
of chills, seven cases of high fever, five cases of nausea and vomit-
ing, and one case each of dyspnea, skin rash and severe irrita-
bility. Hypokalemia (serum potassium level < 3.0 mEq/L) de-
veloped in 15 (46.9%) episodes during amphotericin B deoxy-
cholate therapy in spite of potassium supplementation. Increas-
ed serum creatinine greater than two times the baseline was
observed in three (9.4%) episodes. Finally, antifungal therapy
was completed with voriconazole in 27 (73.0%) episodes.

Mortality at 6 and 12 weeks after antifungal therapy was 16.2% and
27.0%, respectively (Table 3). Between 10 children who died
within 12 weeks after antifungal therapy and 27 children who survived longer than 12 weeks after antifungal therapy, there were no significant differences in the distribution of host factors and clinical and mycological criteria (data not shown). Voriconazole was administered to 77.8% of the children who survived and 60.0% of the children who did not survive (P = 0.407). Voriconazole therapy was begun a median of 7 days (IQR: 4-13) after antifungal therapy in the children who survived and a median of 14 days (IQR: 6-25) after antifungal therapy in the children who did not survive (P = 0.204).

**Comparison between the IPA and non-IPA groups**

Clinical features between the IPA and non-IPA groups were compared in order to identify any significant factors related to the development of IPA in children who received antifungal therapy (Table 1). There were no significant differences in sex, age, underlying disease and its remission status, previous histories of IPA and HCT, and the type therapy administered prior to antifungal therapy between the two groups. However, significantly more children in the IPA group experienced neutropenia lasting for longer than 2 weeks before antifungal therapy (P < 0.001), and accordingly the proportion of children with a total duration of neutropenia longer than 4 weeks was significantly higher in the IPA group compared to the non-IPA group (P < 0.001). Although fever duration was significantly longer in the IPA group than in the non-IPA group, the difference was only one day.

There was no difference in the distribution of host factors for

| Table 1. Characteristics of children receiving antifungal therapy |
|---------------------------------------------------------------|
| **Factors** | **Non-IPA group (n = 228)** | **IPA group (n = 37)** | **P value** |
|---|---|---|---|
| **Gender** | &nbsp; | &nbsp; | &nbsp; |
| Male | 139 (61.0) | 23 (62.2) | 0.890 |
| Female | 89 (39.0) | 14 (37.8) | &nbsp; |
| **Age (yr), mean ± SD** | 10.0 ± 5.4 | 11.4 ± 5.3 | 0.155 |
| **Underlying disease** | &nbsp; | &nbsp; | 0.519 |
| Acute myeloid leukemia | 94 (41.2) | 15 (40.5) | &nbsp; |
| Acute lymphoblastic leukemia | 73 (32.0) | 15 (40.5) | &nbsp; |
| Juvenile myelomonocytic leukemia | 5 (2.2) | 0 (0.0) | &nbsp; |
| Chronic myeloid leukemia | 1 (0.4) | 0 (0.0) | &nbsp; |
| Other leukemias | 6 (2.6) | 1 (2.7) | &nbsp; |
| Lymphoma | 5 (2.2) | 0 (0.0) | &nbsp; |
| Solid tumor | 20 (8.8) | 0 (0.0) | &nbsp; |
| Severe aplastic anemia | 18 (7.9) | 6 (16.2) | &nbsp; |
| Hemophagocytic lymphohistiocytosis | 4 (1.8) | 0 (0.0) | &nbsp; |
| Myelodysplastic syndrome | 1 (0.4) | 0 (0.0) | &nbsp; |
| Other anemias | 1 (0.4) | 0 (0.0) | &nbsp; |
| **Status of underlying disease** | &nbsp; | &nbsp; | 0.144 |
| Complete remission state | 82 (39.4) | 8 (25.8) | &nbsp; |
| Uncontrolled state | 126 (60.6) | 23 (74.2) | &nbsp; |
| **Administered therapy prior to antifungal therapy** | &nbsp; | &nbsp; | 0.715 |
| No chemotherapy | 25 (11.0) | 5 (13.5) | &nbsp; |
| Remission induction chemotherapy | 22 (9.6) | 4 (10.8) | &nbsp; |
| Re-induction or salvage chemotherapy | 76 (33.3) | 13 (35.1) | &nbsp; |
| Consolidation chemotherapy | 43 (18.9) | 4 (10.8) | &nbsp; |
| Maintenance chemotherapy | 5 (2.2) | 1 (2.7) | &nbsp; |
| Palliative chemotherapy | 12 (5.3) | 4 (10.8) | &nbsp; |
| Allogeneic HCT | 36 (15.8) | 6 (16.2) | &nbsp; |
| Autologous HCT | 9 (3.9) | 0 (0.0) | &nbsp; |
| **Previous history** | &nbsp; | &nbsp; | 0.248 |
| Post-HCT state | 94 (41.2) | 19 (51.4) | 0.541 |
| Previous IPA | 19 (8.3) | 4 (10.8) | &nbsp; |
| **Fever duration (days), median (IQR)** | &nbsp; | &nbsp; | &nbsp; |
| Before treatment | 3 (1-5) | 2 (1-4) | 0.017 |
| Total duration | 7 (4-13) | 7 (4-17) | 0.641 |
| **Neutropenia duration** | &nbsp; | &nbsp; | &nbsp; |
| Before treatment | &nbsp; | &nbsp; | < 0.001 |
| ≤ 2 weeks | 178 (78.1) | 18 (48.6) | &nbsp; |
| > 2 weeks | 50 (21.9) | 19 (51.4) | &nbsp; |
| Total duration | &nbsp; | &nbsp; | < 0.001 |
| ≤ 4 weeks | 175 (76.8) | 16 (43.2) | &nbsp; |
| > 4 weeks | 53 (23.2) | 21 (56.8) | &nbsp; |
| Concurrent other infections | 60 (26.3) | 10 (27.0) | 0.927 |

*Complete remission state was determined in 239 episodes (208 in the non-IPA group and 31 in the IPA group). IPA, invasive pulmonary aspergillosis; SD, standard deviation; HCT, hematopoietic cell transplantation; IQR, interquartile range.*
IPA, invasive pulmonary aspergillosis; GMI, galactomannan index; BAL, bronchoalveolar lavage.

Table 2. The application of definitions of invasive aspergillosis recommended by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group

| Factors                        | Non-IPA group (n = 228) | IPA group (n = 37) | P value |
|-------------------------------|-------------------------|--------------------|---------|
| Host factors                  |                         |                    |         |
| Prolonged neutropenia         | 176/228 (77.2)          | 33/37 (89.2)       | 0.097   |
| Allogeneic HCT                | 55/228 (24.1)           | 13/37 (35.1)       | 0.155   |
| Prolonged steroid             | 4/228 (1.8)             | 2/37 (5.4)         | 0.166   |
| Immune suppressant            | 2/228 (0.9)             | 2/37 (5.4)         | 0.095   |
| Clinical criteria             |                         |                    |         |
| Halo sign                     | 48/118 (40.7)           | 29/37 (78.4)       | < 0.001 |
| Consolidation                 | 14/118 (11.9)           | 8/37 (21.6)        | 0.138   |
| Air-crescent                  | 2/118 (1.7)             | 0/37 (0.0)         | 1.000   |
| Cavity                        | 0/118 (0.0)             | 2/37 (5.4)         | 0.056   |
| Mycological criteria          |                         |                    |         |
| Serum GMI positivity          | 27/228 (11.8)           | 30/37 (81.1)       | < 0.001 |
| BAL GMI positivity            | 0/17 (0.0)              | 6/11 (54.5)        | 0.001   |
| BAL fluid Culture positivity  | 1/17 (5.9)              | 2/11 (18.2)        | 0.543   |

Data represent the number of corresponding children/the total number of included children (%). IPA, invasive pulmonary aspergillosis; HCT, hematopoietic cell transplantation; GMI, galactomannan index; BAL, bronchoalveolar lavage.

Table 3. Antifungal therapy and clinical outcomes in children receiving antifungal therapy

| Factors                        | Non-IPA group (n = 228) | IPA group (n = 37) | P value |
|-------------------------------|-------------------------|--------------------|---------|
| Anti-fungal prophylaxis        |                         |                    |         |
| No prophylaxis                | 95 (41.7)               | 11 (29.7)          |         |
| Fluconazole                   | 101 (44.3)              | 21 (56.8)          |         |
| Itraconazole                  | 5 (2.2)                 | 2 (5.4)            |         |
| Micafungin                    | 27 (11.8)               | 3 (8.1)            |         |
| Anti-fungal therapy           |                         |                    |         |
| 1st line therapy              |                         |                    | 0.913   |
| Amphotericin B deoxycholate   | 202 (88.6)              | 33 (89.2)          |         |
| Liposomal amphotericin B      | 12 (5.3)                | 2 (5.4)            |         |
| Caspofungin                   | 2 (0.9)                 | 0 (0.0)            |         |
| Itraconazole                  | 9 (3.9)                 | 2 (5.4)            |         |
| Voriconazole                  | 3 (1.3)                 | 0 (0.0)            |         |
| 2nd line therapy              |                         |                    | < 0.001 |
| Amphotericin B deoxycholate   | 166 (72.8)              | 35 (94.6)          |         |
| Liposomal amphotericin B      | 133 (80.1)              | 16 (45.7)          |         |
| Caspofungin                   | 24 (14.5)               | 6 (17.1)           |         |
| Itraconazole                  | 3 (1.8)                 | 1 (2.9)            |         |
| Voriconazole                  | 4 (2.4)                 | 12 (34.3)          |         |
| Final therapy                 |                         |                    | < 0.001 |
| Amphotericin B deoxycholate   | 44 (19.3)               | 2 (5.4)            |         |
| Liposomal amphotericin B      | 119 (52.2)              | 3 (8.1)            |         |
| Caspofungin                   | 33 (14.5)               | 4 (10.8)           |         |
| Itraconazole                  | 10 (4.4)                | 1 (2.7)            |         |
| Voriconazole                  | 22 (9.6)                | 27 (73.0)          |         |
| Total duration of therapy (days, median IQR) | 12 (7-21) | 73 (22-175) | < 0.001 |

Outcome
|                   | IPA group (n = 37) | P value |
|-------------------|--------------------|---------|
| 6 weeks mortality | 30 (13.2)          | 0.615   |
| 12 weeks mortality| 46 (20.2)          | 0.344   |

IPA, invasive pulmonary aspergillosis; IQR, interquartile range.

Antifungal prophylaxis was administered more frequently in the IPA group; however, the difference was not significant (Table 3). The type of first line antifungal agent was not significantly different between the two groups. However, second line and later administered antifungal agents were significantly different between the two groups - voriconazole and liposomal amphotericin B were most commonly administered in the IPA and non-IPA groups, respectively. Mortality at 6 and 12 weeks after antifungal therapy was higher in the IPA group compared to the non-IPA group, however, the differences were not statistically significant (Fig. 2, P = 0.353).

**DISCUSSION**

In the present study, clinical features and prognosis of IPA diagnosed in children with hematologic/oncologic diseases were investigated, and clinical factors associated with the development of IPA in children who received antifungal therapy were evaluated. Prolonged neutropenia, corticosteroids or immune suppressant therapy, hematologic malignancy as a underlying disease, especially AML, relapsed leukemia, receiving an allogeneic HCT, graft-versus-host disease and cytomegalovirus infection after allogeneic HCT, and other respiratory viral infection after allogeneic HCT were reported as risk factors for IA in
patients with hematologic/oncologic diseases (5, 6, 8, 27-30). In accordance with previous reports, AML was the most frequent underlying disease, and more than half of the children with hematologic malignancies were non-CR status in the present study.

IPA was diagnosed in 14.0% of children who received antifungal therapy in the present study, and the remaining children, over 80.0%, may have experienced adverse effects of the administered antifungal agents, increased medical costs, and prolonged duration of hospitalization due to unnecessary antifungal therapy. We tried to identify clinical factors predicting the development of IPA in those children to reduce unnecessary antifungal therapy in future patients, and only the duration of neutropenia was significantly different between the IPA and non-IPA groups. Because prophylactic fluconazole has been administered to children at risk for IFD in our hospital, we decided to begin empirical or pre-emptive antifungal therapy based on the risk for IA. As a result, antifungal therapy was initiated based on similar clinical criteria for children both in the IPA and non-IPA groups. Other hospitals where antifungal prophylaxis is performed should address such situations in a fashion similar to our hospital. Therefore, the initiation of antifungal therapy should be based not only on clinical features, but also on results of imaging and mycological tests, such as chest CT and serum and BAL fluid GMIs. In the present study, the incidence of halo sign on chest CT was significantly higher in the IPA group compared to the non-IPA group. Although there was no significant difference in outcome between the IPA and non-IPA groups, chest CT was helpful in diagnosing IPA.

Serum GMI is valuable in diagnosing IPA in children and adults (31-33), and the ECIL-4 guidelines recommend a serum GMI > 0.5 as positive (17). Considering 16.2% of the IPA group in the present study showed negative serum GMI results but positive BAL fluid GMI or culture results, BAL fluid analyses should be encouraged in patients in whom IPA is suspected in spite of negative serum GMI results. In addition, bronchoscopy should be performed in the early phase of IPA to acquire reliable BAL fluid GMI results. The ECIL-4 guidelines recommend a BAL fluid GMI > 1.0 as positive (17). However, there have been only a few studies on the application of BAL fluid GMI for diagnosing IPA in children (34, 35), and further studies to determine an appropriate BAL fluid GMI cut-off value for diagnosing IPA should be performed in children.

The 27.0% mortality in the IPA group was lower than recently reported 45% mortality in Korean adult and pediatric patients with IPA (12, 13), although 89.2% of the IPA group received amphotericin B deoxycholate as a first line antifungal agent in the present study. The difference in mortality was assumed to be a result of early changes in antifungal agents from amphotericin B deoxycholate to liposomal amphotericin B or voriconazole in our cases. In addition, about 80% of the IPA group showed halo signs on chest CT, which have been reported as characteristic CT findings in the early phase of IPA as opposed to air-crescent, cavity, and simple consolidation (31, 36). Most patients in the IPA group may have been diagnosed with IPA in the early phase of disease in the present study, and an improved prognosis in IPA patients with halo signs compared to other CT findings has been reported (37).

The present study was performed when amphotericin B deoxycholate or itraconazole were required to be administered as a first line antifungal agent due to government regulation of the national health insurance system in Korea. Now, in 2015, we are able to administer liposomal amphotericin B and caspofungin as first line antifungal agents in febrile neutropenic children based on a modified government policy in 2014. Because first line antifungal agents were adjusted to second line agents due to their adverse effects in more than half of IPA episodes in the present study, more safe and effective antifungal therapy is expected in the future in Korea. Voriconazole treatment was associated with improved survival and fewer side effects compared to amphotericin B deoxycholate treatment of IPA (9), and empirical antifungal therapy with voriconazole was reported to be more economical than empirical therapy with amphotericin B deoxycholate (38, 39). In the present study, almost all IFD cases were IPA and no cases of mucormycosis were reported. In addition, in the IPA group of the present study, children who died received voriconazole therapy later than children who survived, although this difference was not statistically significant. Considering these results, voriconazole as well as liposomal amphotericin B and caspofungin could be considered as a first line antifungal agent in immunocompromised Korean children at risk for IPA to further improve prognosis in those children.

This study has several limitations including its retrospective nature. Cases of IFDs other than IPA were not thoroughly reviewed in the whole population of children with hematologic/oncologic diseases in our hospital. Risk factors for mortality and poor prognosis in children with IPA could not be evaluated due to the small number of children diagnosed with IPA. The enrolled children were heterogeneous - children with various types of underlying diseases were included and children receiving autologous or allogeneic HCT and not receiving HCT were included together. To overcome these limitations, a multicenter study including many children should be performed in the future.

In conclusion, 14.0% of children who received empirical antifungal therapy were diagnosed with IPA. Although amphotericin B deoxycholate was administered as a first line antifungal agent in most cases, mortality at 12 weeks after antifungal therapy was lower than previously reported in Korea. This improvement in prognosis of IPA was assumed to be arisen from early diagnosis of IPA. Therefore, early use of chest CT to identify halo signs in immunocompromised children who are expected to have prolonged neutropenia can be helpful for early diagnosis of IPA and improving prognosis of children with IPA. In addition,
the prognosis of IPA in immunocompromised children is expected to be improved with the introduction of liposomal amphotericin B and caspofungin as first line antifungal agents in the future in Korea.

DISCLOSURE

There is no conflict of interest for all authors.

AUTHOR CONTRIBUTION

Study design: Han SB, Lee DG, Cho B, Kang JH. Data collection and analysis: Han SB, Kim SK, Bae EY, Lee JW, Yoon JS, Chung NG, Jeong DC. Review radiological findings: Lee HS, Im SA. Writing: Han SB, Bae EY, Lee DG, Kang JH. Review and revision: Cho B, Kim HK.

ORCID

Seung Beom Han  http://orcid.org/0000-0002-1299-2137
Seong koo Kim  http://orcid.org/0000-0002-1860-3067
E Young Bae  http://orcid.org/0000-0003-2777-210X
Jae Wook Lee  http://orcid.org/0000-0002-0735-0287
Jong-Seo Yoon  http://orcid.org/0000-0002-5782-6175
Nack-Gyun Chung  http://orcid.org/0000-0003-4855-390X
Bin Cho  http://orcid.org/0000-0001-6675-695X
Dae Chul Jeong  http://orcid.org/0000-0003-0934-817X
Jin Han Kang  http://orcid.org/0000-0003-1610-6742
Hack-Ki Kim  http://orcid.org/0000-0001-7298-4596
Dong-Gun Lee  http://orcid.org/0000-0003-4655-0641
Hyun Sil Lee  http://orcid.org/0000-0001-8695-9113
Soo Ah Im  http://orcid.org/0000-0002-1264-3690

REFERENCES

1. Marr KA, Seidel K, Slavin MA, Bowden BA, Schoch HG, Flowers ME, Corey L, Boechk M. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2053-61.
2. Kaya Z, Gurses T, Kocak U, Aral YZ, Kalkanci A, Albayrak M. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer 2009; 52: 470-5.
3. Mor M, Gilad G, Kornreich L, Fisher S, Yaniv I, Levy I. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011; 56: 1082-7.
4. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
5. Patterson TE, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. III Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250-60.
6. Groll AH, Kurz M, Schneider W, Witt V, Schmidt H, Schneider M, Schwanke D. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 1999; 42: 431-42.
7. Abbasi S, Shenepl JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis 1999; 29: 1210-9.
8. Babor E, Schuster F, Mackenzie C, Meisel R, Schaper J, Sabir H, Siepermann M, Wessalowski R, Janßen G, Borkhardt A, et al. Invasive aspergillosis in pediatric oncology patients: a rare event with poor prognosis-case analysis to plan better targeted prophylactic or therapeutic measurement. Klin Padiatr 2012; 224: 160-5.
9. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, et al.; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
10. Neofytos D, Horn D, Annaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-73.
11. Steinbach WJ, Marr KA, Annaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apezokin S, Horn DL. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012; 65: 453-64.
12. Choi SH, Kang ES, Eo H, Yoo SY, Kim JH, Yoo KH, Sung KW, Koo HH, Kim YJ. Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients. Pediatr Blood Cancer 2013; 60: 316-22.
13. Kim SH, Moon SM, Han SH, Chung JW, Moon SY, Lee MS, Choi EJ, Choi YH, Kim SW, Bae IG, et al. Epidemiology and clinical outcomes of invasive pulmonary aspergillosis: a nationwide multicenter study in Korea. Infect Chemother 2012; 44: 282-8.
14. Kwon JC, Kim SH, Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim YJ, Lee S, Kim HJ, et al. Prognosis of invasive pulmonary aspergillosis in patients with hematologic diseases in Korea. Tuberc Respir Dis (Seoul) 2012; 72: 284-92.
15. Nivoix Y, Velton M, Letscher-Bru V, Moghadam A, Natarajan-Amé S, Fohrer C, Lioure B, Bäger K, Lutten P, Marcellin L, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-84.
16. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1999; 17: 139-47.
17. Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, Rohde E, Styczynski J, Warris A, Lehrnbecher T; Fourth European Conference on Infections in Leukaemia; Infectious Diseases Working Party of the European Group for Blood Marrow Transplantation (EBMT-IDWP); Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC-IDG); International Immunocompromised Host Society (ICHS); European Leukaemia Net (ELN). Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases.
in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014; 15: e257-60.

18. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckx MJ, Ito JJ, Mullen CA, Raad, II, Rolston KV, Young JA, Wingard JR. Infectious Diseases Society of America. Clinical practice guideline for the use of antifungal agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52: e56-93.

19. Caselli D, Cesaro S, Ziino O, Ragusa P, Pontillo A, Pegoraro A, Santoro N, Zanazzo G, Poggi V, Giacchino M, et al. A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children. Br J Haematol 2012; 158: 249-55.

20. Cesaro S, Pagano L, Caira M, Carraro F, Luciani M, Russo D, Colombini A, Morello W, Viale P, Rossi G, et al.; Hema-e-Chart Group. A prospective, multicentre survey on antifungal therapy in neutropenic paediatric haematology patients. Mycoses 2013; 56: 21-5.

21. des Champs-Bro B, Leroy-Cotteau A, Mazingue F, Pasquier F, François N, Corn S, Lemaître L, Poulain D, Yakoub-Agha I, Allandari S, et al. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. J Clin Pharm Ther 2011; 36: 152-60.

22. Grassard N, Hadden H, Piens MA, Pondarré C, Hadden R, Kalamburu C, Pracros JP, Souillet G, Basset T, Berthier JC, et al. Invasive aspergillosis in a paediatric haematology department: a 15-year review. Mycoses 2008; 51: 109-16.

23. Burqos A, Zaatouis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania IJ, Prasad P, Steinbach WJ. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121: e1266-94.

24. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.

25. Lee DG, Kim SH, Kim SY, Kim CJ, Min CK, Park WB, Park YJ, Song YG, Jang JS, Jang JH, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Infect Chemother 2011; 43: 258-321.

26. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF; Perfect JR, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.

27. Marr KA, Carter RA, Boeckx M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.

28. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117: e711-6.

29. Mikulska M, Raiola AM, Bruno B, Furfaro E, Van Lint MT, Bregante S, Ibarici A, Del Bono V, Bacigalupo A, Viscoli C. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44: 361-70.

30. Steinbach WJ. Invasive aspergillosis in pediatric patients. Curr Med Res Opin 2010; 26: 1779-87.

31. Caillot D, Couallier JE, Bernard A, Casasnovas O, Denning DW, Mannone L, Lopez J, Couliaud G, Piard F, Vagner O, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-9.

32. Hayden R, Pounds S, Knapp K, Petraitise R, Schaafiele RL, Sein T, Walsh TJ. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J 2008; 27: 815-9.

33. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100.

34. Desai R, Ross LA, Hoffman JA. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 2009; 28: 263-6.

35. Hsu LY, Ding Y, Phua J, Koh LP, Chan DS, Khoo KL, Tambyah PA. Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematopoietic patients. BMC Infect Dis 2010; 10: 44.

36. Becker MJ, de Marie S, Fens MH, Verbrugh HA, Bakker-Woudenberg IA. Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2003; 52: 428-34.

37. Greene RE, Schlamm HT, Ostemm JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.

38. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwitz M, van Burik JA, Laverdiere M, Sfrain S, Wingard JR. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-66.

39. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.